Importantly, Gαi-coupled GPCRs, including cannabinoid receptors 46, CXCR4 47, 48, dopamine D2 receptors 24 and melatonin receptor II (MTII) 49, were reported to be important for glioma progression. This evidence concerns the gene DRD2 and glioma.